Business
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTX...
About this update from Hemostemix Inc
Hemostemix Closes $480,000 Private Placement at $0.12 per ShareCalgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, and vascular dementia, is pleased to announce that it has closed a non-brokered private placement for aggregate gross proceeds of CDN$480,000, through the issuance of 4,000,000 common shares of the Company at a price of $0.12 per common share.The proceeds from the private placement will be used for general working capital purposes, including advancing the Company's regulatory, clinical, and commercialization initiatives related to ACP-01 (VesCell), Hemostemix's autologous angiogenic cell therapy platform.All securities issued pursuant to the private placement are subject to a statutory hold period in accordance with applicable securities laws and the policies of the TSX Venture Exchange ("TSXV"). The private placement remains subject to final acceptance by the TSXV.ABOUT HEMOSTEMIX Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com. For further inform...